GLP-1 Receptor Agonists

Retatrutide (Triple GIP/GLP-1/Glucagon Agonist)

For Research Use Only. Not for Human or Veterinary Use.

Overview

Retatrutide (development code LY3437943) is a synthetic linear peptide that activates three receptors at once — GIP, GLP-1 and, uniquely for this class, the glucagon receptor (GCGR). Adding glucagon-receptor activity is studied as a way to raise energy expenditure on top of the appetite and glucose effects of the incretin receptors. Like the other agonists in this class it carries a fatty-diacid modification for albumin binding, giving a half-life of about six days.

Chemical Profile

PropertyValue
CAS number2381089-83-3
Development codeLY3437943
ClassGIP / GLP-1 / glucagon (GCGR) triple receptor agonist
Backbone39-amino-acid peptide (GIP-based) with a C20 fatty-diacid conjugation
Molecular weight≈ 4840.58 g/mol
Purity (HPLC)≥ 98%
AppearanceWhite to off-white lyophilized powder
Retatrutide at a glance
Class
GIP / GLP-1 / glucagon triple agonist
Originator
Eli Lilly and Company
Research status
Under clinical investigation
Study route
Subcutaneous, once weekly
Half-life
≈ 6 days
Key feature
First triple incretin/glucagon agonist in development

Mechanism of Action

Retatrutide is a single peptide engineered to activate three class-B GPCRs — GIPR, GLP-1R and GCGR — all of which couple through Gαs to raise cAMP. The research rationale is complementary: the glucagon-receptor arm is studied for increasing energy expenditure and lipolysis, while the GIP and GLP-1 arms provide insulin secretion and appetite effects and are investigated for offsetting glucagon’s tendency to raise glucose.

ComponentDetail
Primary targetsGIPR, GLP-1R and glucagon receptor (GCGR)
Receptor classClass B G-protein-coupled receptors
G-protein couplingGαs → adenylyl cyclase → cAMP (all three)
Downstream signallingPKA, EPAC, CREB, PI3K/Akt; β-arrestin recruitment
Activation profileBalanced activation across the three targets
ReceptorStudied effects
GLP-1RGlucose-dependent insulin secretion, glucagon suppression, satiety
GIPRInsulin secretion, energy expenditure, lipid metabolism
GCGRHepatic glucose handling, energy expenditure, lipolysis, thermogenesis

Pharmacology

ParameterValue
Half-life (t½)≈ 6 days (~138–155 h)
Time to peak (Tmax)12–24 h post-dose
Bioavailability (SC)≈ 75%
Volume of distribution≈ 0.25 L/kg
Protein binding≈ 99% (albumin)
MetabolismProteolytic degradation (no CYP involvement)
EliminationRenal (peptide fragments) and fecal

Research Evidence

Representative studies and trial programs and what they investigated; specific numerical outcomes are not restated here as claims.

Preclinical modelResearch focusReference
Diet-induced obese miceTriple- vs dual-agonism body-weight effectsCoskun T, et al. (2022)
GCGR-knockout miceGlucagon-receptor-dependent energy metabolismKnerr PJ, et al. (2023)
Non-human primatesBody-composition and glycemic effectsSloop KW, et al. (2023)
Clinical programPhaseResearch focusReference
Phase 1 / 2 dose-findingPhase 1–2Safety and dose–responseCoskun T, et al. (2022)
TRIUMPH-1Phase 2Body-weight endpoints in obesity researchJastreboff AM, et al. (2023), NEJM
TRIUMPH-2 / 3Phase 3Ongoing obesity and comorbidity researchEli Lilly clinical program

Representative reported directions from the literature (qualitative; GLP-1 entries reflect published clinical-trial results, others are reported study directions, not restated as precise product claims):

Reported direction / findingContextReference
Marked body-weight reduction (triple agonism)Phase 2 obesityJastreboff AM et al., NEJM 2023
Triple agonism exceeds dual agonism in preclinical modelsDIO miceCoskun T et al., 2022
Added glucagon-receptor arm raises energy expenditurerodent metabolismGCGR knockout studies

For laboratory research use only. Not for human or veterinary use, diagnosis, or therapeutic application. Descriptions refer to published research contexts and are not medical or product claims.

Dosing & Reconstitution Reference

Reconstitution and handling parameters for laboratory research. Not dosing guidance for human use.

ParameterReference value
Research dosing range (literature)0.25–1.2 mg, once weekly (SC), in study protocols
Reconstitution solventBacteriostatic water (0.9% benzyl alcohol)
Final concentration≈ 2.5–5 mg/mL
Storage (lyophilized)−20°C, protected from light
Storage (reconstituted)2–8°C, up to ~14 days
Do not useIf the solution is cloudy or contains particulates

Safety Profile

Published safety observations for the compound, provided as research reference only. This material is not for human or veterinary use.

CategoryPublished observations
Most commonGastrointestinal: nausea, diarrhea, vomiting, decreased appetite (dose-dependent)
CardiovascularModest heart-rate increase reported; significance under investigation
Serious (rare)Pancreatitis and gallbladder-related events at low frequency
Rodent findingThyroid C-cell tumors (class effect in rodent studies)
StatusFor research use only; not for human or veterinary application

Physicochemical Properties

PropertyValue
Physical stateWhite to off-white lyophilized powder
Solubility (water)Freely soluble (> 50 mg/mL)
logP (octanol/water)≈ 4.9
Isoelectric point (pI)≈ 4.9
pH (reconstituted)7.0–8.0
Stability (lyophilized)≥ 24 months at −20°C

Synthesis & Manufacturing

Retatrutide is produced by solid-phase peptide synthesis with the C20 fatty-diacid installed on a lysine side chain after selective deprotection — the same overall route as the other long incretin peptides, with coupling efficiency and preparative HPLC as the key steps.

StepDetail
StrategySolid-phase peptide synthesis, Fmoc/tBu chemistry
ResinRink amide MBHA resin
CouplingHATU / HBTU with DIPEA (double couplings for hindered residues)
Fatty-acid conjugationC20 diacid coupled to a Lys side chain after selective (Mtt) deprotection
CleavageTFA / TIPS / H₂O (95 : 2.5 : 2.5)
PurificationPreparative RP-HPLC (C18, ACN/H₂O + 0.1% TFA gradient)
  • Notes: coupling efficiency and complete Fmoc removal are monitored each cycle; hindered or repeated residues (e.g. Arg-Arg) may need double coupling.
  • Preparative RP-HPLC removes deletion and truncation impurities to reach research-grade purity; salt exchange (lyophilization from dilute HCl) removes residual TFA/acetate.
  • Critical quality attributes: correct molecular weight and low deletion-peptide content. Long peptide with a fatty-diacid modification; confirm the conjugation.

Analytical Methods

MethodParameterTypical result
RP-HPLC (C18, UV 214 nm)Purity≥ 98%
HPLC retentionC18, 25–65% B over 25 minSingle main peak
ESI-MS (positive mode)Identity / mass[M+H]⁺ ≈ 4841 Da (multiply charged)
MALDI-TOFMass confirmation[M+H]⁺ ≈ 4841 Da (multiply charged)
Amino-acid analysisCompositionConsistent with the stated sequence
LC-MS (extracted ion)Deletion-peptide impuritiesWithin specification
Karl FischerWater content< 6%
LAL assayEndotoxinWithin specification
Ion chromatographyResidual TFA< 500 ppm

Representative RP-HPLC purity method:

  • Column: C18, 5 µm, 250 × 4.6 mm
  • Mobile phase A: 0.1% TFA in water · Mobile phase B: 0.1% TFA in acetonitrile
  • Gradient: 25–65% B over 25 min · Flow rate: 1.0 mL/min · Detection: UV 214 nm
  • Confirmatory LC-MS: ESI positive mode ([M+H]⁺ ≈ 4841 Da (multiply charged)). Long peptide with a fatty-diacid modification; confirm the conjugation.

Stability Data

Representative stability behaviour under common storage, handling and formulation conditions.

ConditionDurationResult
Lyophilized, −20°C, dark≥ 24 monthsNo significant degradation (purity > 97%)
Lyophilized, 2–8°C, dark≥ 12 monthsMinimal degradation (purity > 95%)
Lyophilized, 25°C (accelerated)3 months< 5% degradation
Reconstituted, 2–8°C, dark7–14 daysMinor degradation
Reconstituted, 25°C24–48 hUse promptly
Light exposure (ICH Q1B)1.2 M lux·hGenerally light-stable
Freeze–thaw (−20°C ⇄ 25°C)3 cyclesAcceptable — aliquot to avoid repeats
  • Keep lyophilized powder cold, dry and light-protected; keep any solution refrigerated and protected from light.
  • Minimise freeze-thaw cycles; aliquot material used across many sessions.
  • Key factor: Long peptide with a fatty-diacid modification; confirm the conjugation.

Selected References

  • Coskun T, et al. LY3437943, a novel GIP, GLP-1 and glucagon receptor triagonist. Nature Metabolism / Cell Metabolism, 2022.
  • Knerr PJ, et al. Glucagon-receptor contribution to the metabolic effects of a triple agonist. Molecular Metabolism, 2023.
  • Jastreboff AM, et al. Triple-hormone-receptor agonist retatrutide for obesity. New England Journal of Medicine, 2023.

Quality & Supply

  • HPLC ≥ 98% purity with a Certificate of Analysis per batch
  • Identity confirmed by LC-MS; endotoxin tested by LAL
  • Research samples through to bulk, with worldwide delivery
  • Custom quantities and packaging on request

Need Retatrutide — sample or bulk?

HPLC-verified, COA per batch. Tell us the quantity you need.

Request a Quote